Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Key Takeaways Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant lowered its 2024 full-year revenue forecast.This tepid outlook ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 37.85% higher than today’s price of $747.20.

Indianapolis-based drugmaker Eli Lilly and Company has announced price reductions of 70% for its most commonly prescribed insulins, as well as expansion of its Insulin Value Program, capping ...

Eli Lilly (NYSE:LLY) has reportedly asked the Biden administration to pause negotiations over drug pricing, citing problems with the process. Lilly CEO Dave Ricks said in an interview that the ...

Eli Lilly & Co. (LLY) is rebounding from Friday's sales disappointment, finding support at $722 and set for another uptrend.

Eli Lilly has responded to criticism of high prices for insulin products in the US by launching a cut-price version of its Humalog brand. The ‘authorised generic’ uses the same insulin lispro ...

The list price of Zepbound is $1,086.37 per fill, according to a pricing plan Lilly announced last year but the amount someone pays depends “on your prescription drug insurance plan,” the ...

Eli Lilly (LLY) ended the recent trading session at $797.48, demonstrating a -0.3% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0. ...